METHOD OF TREATING TONGUE CANCER Russian patent published in 2013 - IPC A61N5/01 A61N7/00 A61K31/282 A61K31/337 A61K35/14 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for treating patients with tongue cancer. For this purpose, on the 1^st therapeutic day, taxotere 100 mg/m² and cisplatin 50 mg/m² are introduced intravenously drop-by-drop. One week later, a primary site and regional metastases are exposed distant gamma-therapy by accelerated fractionation in a single basic dose of 2.4 Gy fractionated by 1.2 Gy every 5 hours to a total basic dose of 40 isoGy. Every second day, in the middle of the 5-hour interval of the separate radiation fractions, platidiam 5 mg dissolved in actovegin gel is administered to the primary site, while the tumour is exposed to ultrasound at frequency 880 kHz and intensity 0.4 Wt/cm² for 5 minutes. The therapeutic course is 9 administrations. After the 2-week interval of the radiation therapy, the chemotherapy is repeated as specified in the above regimen. The distant gamma-therapy in a single basic dose of 2.4 Gy, 1.2 Gy every 5 hours is conducted to a total basic dose of 60±4 isoGy. Between the radiation fractions, platidiam 5 mg dissolved in actovegin gel is administered to the primary site, while the tumour is exposed to ultrasound at frequency 880 kHz and intensity 0.4 Wt/cm² for 5 minutes. The therapeutic course is 5 administrations.

EFFECT: method provides improving the therapeutic effect and quality of life in the patients with regional tongue cancer, including through a combination of the systemic and local administration of cytotoxic drugs, the effect of sonosensitisation and deeper penetration of the chemotherapeutic preparation into the full-thickness tumour as ensured by the intensive effect of ultrasound with underlying radiation therapy.

1 ex